Congruence Therapeutics has announced the completion of a $39.5m financing round to advance its portfolio of small molecule correctors into the clinic.
The portfolio includes programmes targeting melanocortin 4 receptor (MC4R)-deficient genetic obesity, glucocerebrosidase 1 (GBA1)-driven Parkinson’s disease, and Alpha-1 antitrypsin deficiency.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The financing was co-led by Dimension and OrbiMed, with additional participation from Amplitude Ventures, BDC Capital’s Thrive Venture Fund, Driehaus, FSTQ, Investissement Quebec, Lumira and Silver Arc.
It will primarily fund the Phase I/Ib study of CGX-926, Congruence Therapeutics’ lead programme for MC4R-deficient genetic obesity, enrolling both healthy subjects and patients.
Congruence Therapeutics also plans to complete investigational new drug (IND)-enabling activities for two development candidates focused on GBA1-driven Parkinson’s disease and Alpha-1 antitrypsin deficiency.
The company aims to submit clinical trial application (CTA) / IND applications for these programmes in early 2027.
Congruence Therapeutics co-founder and CEO Dr Clarissa Desjardins said: “Our mission is to translate biology, chemistry and protein structural insights into medicines that address disease at its molecular origin.
“In addition to CGX-926, we are advancing multiple proprietary and collaborative programmes. We thank our new and existing investors for their continued support.”
Dimension’s founder and managing partner Zavain Dar said: “Leveraging cutting-edge molecular dynamics and machine learning, Congruence has built a best-in-class platform to unlock an exciting modality of medicines in small molecule correctors.”
Congruence continues research collaborations, including an expanded multi-target partnership with Ono Pharmaceuticals covering neurology, immunology, and oncology targets.
Another collaboration involves drug discovery for a metabolic target with a global pharmaceutical company.
The company’s Revenir computational platform analyses dynamic protein states to predict small molecule modulation, supporting its pipeline of genetically validated targets with unmet medical needs.
